Dr. Donald Davidson co-founded Creative BioTherapeutics to create next generation therapies to treat late stage resistant and metastatic cancers.
His approach is radically different from large pharmaceutical and other biotech companies. Dr. Davidson has been researching thrombolytics (blood chemistry) and cancer for over 30 years, with much of that time at a large pharmaceutical company. From his ground breaking research in angiogenesis (starve tumor of blood supply), he has generated several patents, papers and cancer drugs that have been tested in clinical trials.
Recent advancements in Dr. Davidson’s lab at CBT have led to the discovery of a novel escape route for late stage, metastatic, drug resistant lung, breast, colon and brain cancer tumor cells. From these developments, novel, innovative, first-in-class inhibitors for this resistant, survival pathway have been discovered and created. In addition, this same escape route is essential for virus (COVID-19, Influenza A) entry and replication. Currently, we are testing these inhibitors in anti-cancer and anti-viral assays.
Donald Davidson, PhD
Chief Executive Officer | Co-Founder
Dr. Donald Davidson has extensive experience in drug development from early discovery to patient treatment in the fields of thrombolytics, oncology and immunology. Throughout his career he has been a maverick on the forefront of biochemical discovery with a strong background in the science of the disease mechanisms that cross several areas of specialty.
As a result of his passion to explore the underlying cross relationships of disease, he has developed expertise in the scientific areas of Thrombolytics (study of clotting), Oncology (study of cancer), Immunology (study of the immune system) and Virology (study of viruses). By understanding the biochemical cross relationships that drive cancer development and resistance to treatment he has discovered that all 4 areas of science play a role in the cause of the disease leading to the discovery of potential cures. Likewise, his understanding of the survival pathways of disease has led to the ability to treat COVID-19.
Anita Davidson, DPT
President | COO | Co-Founder
Dr. Anita Davidson holds a doctorate in physical therapy with over 39 years in healthcare as both a clinician and a business leader. Anita has been a serial entrepreneur with development of several successful business ventures with proven collaborative skills and communication. She brings her extensive business development, financial management and administrative experience to CBT to support the creative process. As a noted change agent, she has been integral in business and program commercialization for several large scale, hospital wide projects in two medical centers while maintaining clinical responsibilities. Developing programs and consulting hospital wide was the hallmark of her time prior to beginning her current private practice that has been successful for the past 24 years.
In addition to her operational and development responsibilities, Anita is the liaison between investors and the research process. As CBT moves from pre-clinical to market entry, she will oversee the company staffing, facilities, and operational expansion to support future work in virus and cancer markets as she is passionate about bringing potential cures to those that are in the greatest need.
CBT employs a decentralized business model using Top Tier CROs and advisors to reduce cost and increase efficiency as it moves to the market. Internal team expansion will progress as preparation for market entry is underway during clinical trials.
Elizabeth Stolarik
Research Scientist
Elizabeth “Lyzzi” Stolarik, Research Scientist, has a background in Neuroscience and has been critical in the research process for virus, cancer and neuroscience studies.
Thanks to the National Science Foundation’s support of STEM studies, CBT has been able to receive additional funding for 2 outstanding summer interns to assist with the research process.
